Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Investor Presentation (November 2021)
35 slides from Jubilant Pharmova's investor presentation, November 2021
Slide 1: Investor Presentation November 2021
Investor Presentation November 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Jubilant Pharmova Limited – Overview
Jubilant Pharmova Limited – Overview Jubilant Pharmova Limited Jubilant Life FY21 Revenue Split (Continuing Business) Sciences Limited renamed as Segment Wise Region Wise 100% Jubilant Pharmova China and ROW India CRDS Limited on Feb 1, 7% 5% Jubilant Pharma Limited 5% 2021. Company Specialty Europe
Slide 4: Jubilant Pharmova – Business Snapshot
Jubilant Pharmova – Business Snapshot Pharmaceuticals Contract Research and Development Services Specialty Pharmaceuticals Fully integrated Drug Discovery services provider 1 #3 radiopharmaceutical manufacturer in the US Facilities in Noida and Bangalore Radio Manufacturing facility based in
Slide 5: High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities
High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities Biosys Noida Facility Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapy Roorkee, Uttarakhand Generics manufacturing Noida Montreal, Canada Corporate Office Contract Ma
Slide 6: Experienced Management Team with High Standards of Corporate Governance
Experienced Management Team with High Standards of Corporate Governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 41 industry years in pharma, specialty 35 industry years in pharma, specialty chemicals, chemicals, foods, oil and gas, aerospace and IT foods, oil and gas,
Slide 7: Pharmaceuticals Business - Jubilant Pharma
Pharmaceuticals Business - Jubilant Pharma
Slide 8: Pharmaceuticals Business Structure and Evolution: Strong M&A track record
Pharmaceuticals Business Structure and Evolution: Strong M&A track record FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY21 JLL acquired API Acquired Created R&D Acquired a majority Acquired Acquired Draxis Commissioned Acquired Consolidation of Completed JPL enter
Slide 9: Each of the businesses operate in growing markets with considerable headroom for growth
Each of the 6 businesses operate in growing markets with considerable headroom for growth Market Growth Segments Business Units Market Dynamics Size, $Bn Outlook High barriers to entry (complex manufacturing, customer Specialty Radio- stickiness, and stringent regulations) and limited price 6-8% Pha
Slide 10: Each of the six businesses are at different stages of evolution
Each of the six businesses are at different stages of evolution Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable growth Radiopharmaceuti
Slide 11: Looking ahead, markers are in place for sustained/accelerated growth across portfolio
Looking ahead, markers are in place for sustained/accelerated growth across portfolio Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable g
Slide 12: Sustained out-performance to be driven by five key differentiators
Sustained out-performance to be driven by five key differentiators • Businesses with different market dynamics and stage of evolution 1 • US-centric front-end and manufacturing help drive innovation and is supported by robust operations from India 1 2 • Specialty businesses have leadership in the US
Slide 13: Business Overview
Se |! _ Business Overvi a *o .
Slide 14: Radiopharmaceuticals – Business Overview
Radiopharmaceuticals – Business Overview Uncompromised Quality Innovation Leadership • Founded in 1955, acquired by Jubilant Pharma in 2008 • The essence of Jubilant Radiopharma is a • #3 radiopharmaceutical manufacturer in commitment to the highest quality. Our the US based on revenue • Headquarter
Slide 15: Radiopharmacies – Business Overview
Radiopharmacies – Business Overview # 2 commercial radiopharmacy network in the US Facilities also include three operational cyclotrons Multi-year agreements with GPOs in place 48 SPECT radiopharmacies spread across 22 states Access to 13 PET radiopharmacies via SOFIE 750+ employees c.2.8 mn+
Slide 16: Allergy Immunotherapy (AIT) – Business Overview
Allergy Immunotherapy (AIT) – Business Overview Products Product range includes portfolio of 100+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices #2 player in the allergenic SCIT extract market in the US and the sole supplier for venom immun
Slide 17: CMO – Business Overview
CMO – Business Overview Overview CMO Services across product segments Sterile injectables accounts for 80% CMO revenue while non-sterile products Full suite of services to our customers including supply chain support, account for the balance 20% CMO revenue lab testing services, regulatory submiss
Slide 18: API – Business Overview
API – Business Overview Highlights Top Products1 • ~60% API sales are to regulated markets, resulting in high customer retention levels Jubilant’s Market Share Product • 75–80% sales to third-party customers and balance to internal generics business (FY2020)1 • ~80% of the commercialized portfolio i
Slide 19: Generics – Business Overview
Generics – Business Overview Overview Jubilant's Market Share in select products in US Products Market Share No Of Competitors Market leader in the US in select products(1) Prochlorperazine 100% 0 Capabilities in multiple dosage forms Terazosin 96% 1 Methylprednisolone 29% 5 Vertical integrati
Slide 20: Contract Research & Development Services - Business Overview
Contract Research & Development Services - Business Overview Overview Discovery Services up to IND & GMP Provides new Drug Discovery services to global innovators in US, EU, Full suite of services to our customers including supply chain support, lab testing services and project management Japan & A
Slide 21: Jubilant Therapeutics: developing best-in-class precision therapies in oncology and autoimmune diseases
Jubilant Therapeutics: developing best-in-class precision therapies in oncology and autoimmune diseases State-of-the-art Proven discovery engine with structure-based drug discovery expertise and a track record Discovery of partnerships with biotech and large pharma. Rapid discovery capabilities for
Slide 22: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases Licensed to 22
Slide 23: Jubilant Pharmova - Financials
Jubilant Pharmova - Financials
Slide 24: Financial Performance | P&L
Financial Performance | P&L Revenue from Operations Revenue by Segment 4% 5% 5% 6% 5,976 6,099 19% 24% 26% 23% 26% (Rs Crore) 3,292 33% 29% 31% 2,747 51% 41% 38% 39% FY20 FY21 H1 FY21 H1 FY22 FY20 FY21 H1 FY21 H1 FY22 Specialty Pharma CDMO Generics CRDS EBITDA PAT Margin 26.5% 23.2% 19.5% 22.0% 11.3
Slide 25: Financial Performance | Balance Sheet
Financial Performance | Balance Sheet Return On Capital Employed (ROCE) Leverage Net Debt/ EBITDA 1.41x 1.36x 16.3% 3,361 (% age) 2,600 (Rs Crore) 14.2% 2,237 1,928 FY20 FY21 FY20 FY21 Gross Debt Net Debt Capital Expenditures Working Capital 5.0% 4.5% 94 86 296 1540 (Rs Crore) (Rs Crore) 276 1429 FY
Slide 26: API Demerger Announcement
API Demerger Announcement
Slide 27: Corporate Announcement
Corporate Announcement The Board of Directors of Jubilant Pharmova Limited (“JPM”), at its meeting held on July 23, 2021, has approved the demerger of the Board Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited (“JGL” - a wholly owned subsidiary of the Company) Approva
Slide 28: The reorganisation will ensure presence across the value chain
The reorganisation will ensure presence across the value chain Patent Life On - patent Off Patent Type of Discovery Development Commercialization Service Research Discovery Preclinical Clinical Registration Manufacturing Drug Drug discovery DMPK Phase I trials Approval Pharmacological Permission to
Slide 29: Annexure
Annexure 29
Slide 30: Financial Performance | Q2'FY22
Financial Performance | Q2’FY22 Particulars 1,2 Q2'FY21 Q2'FY22 YoY (%) Revenue Pharmaceuticals 1,516 1,543 2% Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21 Contract Research and Development Services 75 108 44% Proprietary Novel Drugs 0 2 - Pharmaceuticals revenue at Rs 1,543 Cr
Slide 31: Financial Performance | FY21
Financial Performance | FY21 Particulars1,2 FY20 FY21 YoY (%) Revenue Pharmaceuticals 5,714 5,790 1% LSI business demerged from February 1, 2021 into Jubilant Ingrevia. Continuing business revenue was Rs 6,099 Crore versus Rs 5,976 Crore Specialty Pharma 3,019 2,303 (24%) in FY20 CDMO 1,536 2,010
Slide 32: Appendix
Appendix 32
Slide 33: Income Statement – Q2 & H1 FY22
Income Statement – Q2 & H1 FY22 1,2 Particulars Q2'FY21 Q2'FY22 YoY (%) H1'FY21 H1'FY22 YoY (%) Total Revenue from Continuing Operations Pharmaceuticals 1,516 1,543 2% 2,612 3,085 18% Contract Research and Development Services 75 108 44% 132 196 49% Proprietary Novel Drugs 0 2 - 4 2 - Unallocable Co
Slide 34: For more information
For more information For Investors: For Investors: Siddharth Rangnekar VineetVineet V MayerV Mayer CDR India Rangnekar Siddharth Ph: +91Ph: +91 120 436120 436 1103 1103 Ph: +91India CDR +91 9769919966 E-mail:E-mail: vineet.mayer@jubl.com vineet.mayer@jubl.com E-mail: siddharth@cdr-india.com Ph: +91
Slide 35: Thank You
Thank You Corporate Office 1-A, Sector-16A, Noida-201301, UP, India Email: support@jubl.com 35
Jubilant Pharmova — Investor Presentation (November 2021) on 6ix